000504 南华生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-3.321-20.795-81.291-88.52836.260
总资产报酬率 ROA (%)-1.243-4.253-2.055-3.1471.978
投入资产回报率 ROIC (%)-1.896-8.426-6.075-12.7803.605

边际利润分析
销售毛利率 (%)65.16168.06364.79270.83155.525
营业利润率 (%)-19.635-33.419-13.052-19.57910.790
息税前利润/营业总收入 (%)-19.798-26.025-4.978-10.36812.679
净利润/营业总收入 (%)-20.647-34.198-14.704-21.1358.336

收益指标分析
经营活动净收益/利润总额(%)52.42046.05332.10162.241104.845
价值变动净收益/利润总额(%)-2.491-2.1330.2551.033-1.192
营业外收支净额/利润总额(%)0.060-2.246-21.290-1.4470.127

偿债能力分析
流动比率 (X)1.7201.4480.9150.9771.147
速动比率 (X)1.6531.4240.9050.9561.111
资产负债率 (%)49.48060.50385.50983.26675.819
带息债务/全部投入资本 (%)39.70140.10585.15781.178--
股东权益/带息债务 (%)144.759141.4677.62110.55235.384
股东权益/负债合计 (%)86.67255.0542.9613.0316.301
利息保障倍数 (X)130.541-3.907-0.861-1.1616.760

营运能力分析
应收账款周转天数 (天)396.049371.056318.839442.3730.000
存货周转天数 (天)133.48662.46738.635100.7510.000